![Dynorphin/kappa-opioid receptor control of dopamine dynamics: Implications for negative affective states and psychiatric disorders - ScienceDirect Dynorphin/kappa-opioid receptor control of dopamine dynamics: Implications for negative affective states and psychiatric disorders - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0006899318304888-gr2.jpg)
Dynorphin/kappa-opioid receptor control of dopamine dynamics: Implications for negative affective states and psychiatric disorders - ScienceDirect
![Signaling Properties of Structurally Diverse Kappa Opioid Receptor Ligands: Toward in Vitro Models of in Vivo Responses | ACS Chemical Neuroscience Signaling Properties of Structurally Diverse Kappa Opioid Receptor Ligands: Toward in Vitro Models of in Vivo Responses | ACS Chemical Neuroscience](https://pubs.acs.org/cms/10.1021/acschemneuro.9b00195/asset/images/medium/cn-2019-00195v_0008.gif)
Signaling Properties of Structurally Diverse Kappa Opioid Receptor Ligands: Toward in Vitro Models of in Vivo Responses | ACS Chemical Neuroscience
![Frontiers | A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists Frontiers | A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists](https://www.frontiersin.org/files/Articles/447554/fphar-10-00407-HTML/image_m/fphar-10-00407-g002.jpg)
Frontiers | A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists
![Will peripherally restricted kappa‐opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential? - Albert‐Vartanian - 2016 - Journal of Clinical Pharmacy and Therapeutics - Wiley Online Library Will peripherally restricted kappa‐opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential? - Albert‐Vartanian - 2016 - Journal of Clinical Pharmacy and Therapeutics - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/ff659c0a-df99-4a5e-8df9-c1e1925ea7d0/jcpt12404-fig-0001-m.jpg)
Will peripherally restricted kappa‐opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential? - Albert‐Vartanian - 2016 - Journal of Clinical Pharmacy and Therapeutics - Wiley Online Library
![Kappa-opioid receptor-dependent changes in dopamine and anxiety-like or approach-avoidance behavior occur differentially across the nucleus accumbens shell rostro-caudal axis - ScienceDirect Kappa-opioid receptor-dependent changes in dopamine and anxiety-like or approach-avoidance behavior occur differentially across the nucleus accumbens shell rostro-caudal axis - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0028390820304093-fx1.jpg)
Kappa-opioid receptor-dependent changes in dopamine and anxiety-like or approach-avoidance behavior occur differentially across the nucleus accumbens shell rostro-caudal axis - ScienceDirect
![A unique natural selective kappa-opioid receptor agonist, salvinorin A, and its roles in human therapeutics - ScienceDirect A unique natural selective kappa-opioid receptor agonist, salvinorin A, and its roles in human therapeutics - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0031942217300420-fx1.jpg)
A unique natural selective kappa-opioid receptor agonist, salvinorin A, and its roles in human therapeutics - ScienceDirect
![Topical administration of the kappa opioid receptor agonist nalfurafine suppresses corneal neovascularization and inflammation | Scientific Reports Topical administration of the kappa opioid receptor agonist nalfurafine suppresses corneal neovascularization and inflammation | Scientific Reports](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-021-88118-6/MediaObjects/41598_2021_88118_Fig7_HTML.png)
Topical administration of the kappa opioid receptor agonist nalfurafine suppresses corneal neovascularization and inflammation | Scientific Reports
Structure-Based Discovery of New Antagonist and Biased Agonist Chemotypes for the Kappa Opioid Receptor | Journal of Medicinal Chemistry
![Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA) Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA)](https://nida.nih.gov/sites/default/files/images/valenza_zamarripa_promo.jpg)
Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA)
![Kappa Opioid Receptor Structure Revealed, A Potential Milestone in Medication Development | National Institute on Drug Abuse (NIDA) Kappa Opioid Receptor Structure Revealed, A Potential Milestone in Medication Development | National Institute on Drug Abuse (NIDA)](https://nida.nih.gov/sites/default/files/che-image-web.jpg)
Kappa Opioid Receptor Structure Revealed, A Potential Milestone in Medication Development | National Institute on Drug Abuse (NIDA)
![Kappa opioid receptor signaling in the brain: Circuitry and implications for treatment - ScienceDirect Kappa opioid receptor signaling in the brain: Circuitry and implications for treatment - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0278584615000020-fx1.jpg)